| Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape |
|
Immunotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment |
|
International Journal of Molecular Sciences |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study |
|
Advances in Therapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations |
|
Advances in Therapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML |
|
Aging |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Calculator-free point-of-care prognostication in myelodysplastic syndromes. |
|
Am J Hematol |
Myelodysplastic Syndromes (MDS) |
| Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry |
|
Am J Hematol |
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| How I Diagnose Low-Grade Myelodysplastic Syndromes |
|
American Journal of clinical Pathology |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
